ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04471974

Recruitment Status : Recruiting

First Posted : July 15, 2020

Last Update Posted : December 22, 2020

See Contacts and Locations

Sponsor:

Collaborators:

Zenith Epigenetics

Merck Sharp & Dohme Corp.

U.S. Army Medical Research and Development Command

Information provided by (Responsible Party):

Rahul Aggarwal, University of California, San Francisco

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	December 31, 2025
Estimated Study Completion Date :	December 31, 2025

To Top